Evolus (EOLS) AI Stock Analysis

• Market Cap: $316.19M
• Dividend Yield: N/A
• Average Volume (3M): 1.28M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: 15.10%
• EPS Growth: 0.18%
• Country: US
• Employees: 372
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.04
• Shares Outstanding: 65,059,990
• 10 Day Avg. Volume: 2,444,487
• 30 Day Avg. Volume: 1,275,911
• PEG Ratio: 6.72
• Price to Book (P/B): -18.55
• Price to Sales (P/S): 1.44
• P/FCF Ratio: -9.38
• Enterprise Value/Market Cap: 1.32
• Enterprise Value/Revenue: 1.40
• Enterprise Value/Gross Profit: 2.13
• Enterprise Value/Ebitda: -15.10
• 1Y Price Target: $14.50
• Price Target Upside: 200.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.13
• Revenue Forecast (FY): $330.24M

• Rating: 49 Neutral
• Price Target: $5.00 ▲(3.52% Upside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is held back primarily by weak financial performance (ongoing losses, negative cash flow, and negative equity with rising debt). Offsetting this, the latest earnings call supports a credible near-term profitability trajectory with continued revenue growth, while technicals and valuation provide only moderate support due to mixed momentum signals and lack of profitability/dividend.

Positive Factors

Revenue Scaling

Evolus has materially scaled revenue from roughly $56.5M in 2020 to ~$295M in 2025, showing sustained demand and commercial execution. Persistent double-digit top-line growth supports durable operating leverage opportunities and expands the company's ability to absorb fixed costs while funding product expansion.

High Gross Margins

Consistently high gross margins (~66%–67%) indicate attractive unit economics in injectable aesthetics. Strong product-level margins provide structural resilience to pricing pressure and tariffs, enabling the company to reinvest in marketing and international expansion while supporting a credible path to adjusted EBITDA profitability.

Product & International Expansion

New product (Evolysse) early adoption plus accelerating international sales diversify revenue beyond Jeuveau. Broader product portfolio and geographic expansion reduce single-market dependency, raise the addressable market, and support medium-term growth as Evolysse sampling, Sculpt approval, and European launches scale commercial penetration.

Negative Factors

Leverage & Negative Equity

Rising debt and negative equity materially constrain financial flexibility and increase refinancing and covenant risk. A stressed capital structure elevates the probability that management must allocate cash to interest and debt service, limiting capital available for marketing, inventory build for launches, or buffering downside in procedural demand.

Negative Cash Flow

Continued negative operating and free cash flow means the business remains cash-consuming despite improved trends. Structural reliance on external financing or credit facilities to fund working capital and launches heightens execution risk, and persistent cash burn can magnify dilution or raise funding costs if markets tighten.

Tariffs & Competitive Headwinds

Structural margin pressure from import tariffs on Evolysse and intensified competitive sampling from new neurotoxin launches pose ongoing cost and market-share risks. These factors can reduce realized margins and require sustained marketing and sampling investments to defend account share, pressuring long-term profitability unless offset elsewhere.

Evolus Business Overview & Revenue Model

Company Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

How the Company Makes Money

Evolus makes money primarily by selling Jeuveau to healthcare providers (e.g., dermatology, plastic surgery, and aesthetic medical practices) that purchase the product and administer it to patients for cash-pay aesthetic procedures. Revenue is generated per unit/vial sold into these practices, with demand influenced by patient utilization, practice inventory purchasing, and pricing/discounting programs. Outside the United States, the company also generates revenue through commercialization arrangements for Jeuveau in select international markets (via partners and/or regional distribution depending on the country), typically earning revenue from product sales to those partners/distributors and/or other contractually defined economics tied to commercialization. Significant factors that can contribute to earnings include the size and productivity of the company’s aesthetics-focused salesforce, consumer and physician marketing that drives patient demand, and the breadth and terms of its supply/manufacturing and commercialization partnerships for producing and distributing Jeuveau; specific partner names or detailed contractual terms not provided here are null.

Evolus Financial Statement Overview

Summary

Strong revenue scaling and healthy gross margins are offset by continued net losses, negative operating/free cash flow, and a stressed capital structure (negative equity and rising debt), leaving elevated funding and execution risk despite improving trends.

Income Statement

Revenue has scaled meaningfully over time (about $56.5M in 2020 to $295.0M in 2025), and gross margin remains strong (~67% in 2025), suggesting attractive unit economics. However, profitability is still weak: 2025 shows a net loss of ~$51.6M and a net margin around -17.5%, with EBITDA also negative (about -22.9% margin). While losses have narrowed substantially versus 2020, the company has not yet demonstrated consistent operating leverage to reach profitability.

Balance Sheet

Leverage and capitalization are the key concerns. Total debt rose to ~$146.1M in 2025, and stockholders’ equity turned negative in 2025 (about -$23.1M), which reduces financial flexibility and increases refinancing/raise-the-capital risk. Total assets are ~$225.9M, but the negative equity profile and elevated leverage metrics over multiple years point to a weaker balance-sheet cushion despite the company’s growth.

Cash Flow

Cash generation remains a headwind: operating cash flow was negative in 2025 (about -$42.3M) and free cash flow was also negative (about -$45.7M). Free cash flow worsened versus 2024 (negative growth), indicating the business is still consuming cash to support operations and growth. While losses and cash burn have improved materially versus earlier years (notably 2022), the company has not yet transitioned to self-funding cash flow.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	297.18M	266.27M	202.09M	148.62M	99.67M
Gross Profit	192.76M	182.30M	140.53M	89.77M	56.14M
EBITDA	-28.86M	-25.00M	-41.81M	-53.85M	-39.06M
Net Income	-51.64M	-50.42M	-61.69M	-74.41M	-46.81M
Balance Sheet
Total Assets	225.87M	232.57M	189.00M	177.98M	257.48M
Cash, Cash Equivalents and Short-Term Investments	53.83M	86.95M	62.84M	53.92M	146.26M
Total Debt	155.00M	129.98M	126.55M	74.42M	74.74M
Total Liabilities	248.97M	227.05M	209.69M	159.48M	175.61M
Stockholders Equity	-23.11M	5.52M	-20.69M	18.50M	81.88M
Cash Flow
Free Cash Flow	-45.71M	-19.47M	-35.63M	-87.85M	-34.36M
Operating Cash Flow	-42.27M	-18.00M	-34.01M	-84.91M	-33.39M
Investing Cash Flow	-8.45M	-4.82M	-1.63M	-2.94M	4.03M
Financing Cash Flow	17.34M	47.41M	44.64M	-4.15M	73.05M

Evolus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EOLS, the sentiment is Negative. The current price of 4.83 is below the 20-day moving average (MA) of 4.83, below the 50-day MA of 4.87, and below the 200-day MA of 6.91, indicating a bearish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 47.97 is Neutral, neither overbought nor oversold. The STOCH value of 12.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EOLS.

Evolus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DERM	57 Neutral	$231.13M	-19.19	-39.94%	―	2.82%	60.26%
EBS	53 Neutral	$418.31M	12.57	9.59%	―	-29.91%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EOLS	49 Neutral	$316.19M	-8.30	267.84%	―	15.10%	0.18%
ORGO	47 Neutral	$308.74M	17.73	9.56%	―	2.24%	-67.56%
AQST	47 Neutral	$495.50M	-6.18	195.65%	―	-26.32%	-56.54%
RMTI	42 Neutral	$40.59M	-6.17	-16.77%	―	-23.60%	-179.33%

Evolus Corporate Events

Evolus Secures New Credit Facility and Reports Profitability

On March 3, 2026, Evolus secured a new senior secured asset-based revolving credit facility of up to $30 million, with an uncommitted $10 million accordion, maturing in 2029 and secured by substantially all company assets, which adds liquidity but introduces ongoing covenant constraints and collateralized leverage. The facility, priced at adjusted term SOFR plus a margin and subject to minimum utilization and excess availability requirements, gives the company added financial flexibility to manage working capital and capital structure as it scales its injectable aesthetics portfolio.

Also on March 3, 2026, Evolus reported 2025 results showing total net revenue of $297.2 million, up 12% year over year, and fourth-quarter GAAP operating income of $4.2 million, marking a move into profitability after expense reductions and delivering a sixth consecutive year of double-digit growth. The company tightened operating costs, boosted cash to $53.8 million by year-end, and issued 2026 guidance for 10% to 13% revenue growth and modestly rising non-GAAP operating expenses, positioning it for sustainable profitability and expanding margins as new HA gel products and international launches contribute more meaningfully to growth.

The most recent analyst rating on (EOLS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.